Enveric Biosciences (NASDAQ:ENVB) shares plunged 40% premarket on Friday after the biotechnology company priced its securities offering to raise approximately $5M.
The offering comprises 1.66M shares of the company’s common stock (or common stock equivalents in lieu thereof), Series A warrants to purchase up
